Department of Radiation Oncology, University Hospital LMU Munich, Munich, Germany; Clinical Cooperation Unit Molecular Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):516-527. doi: 10.1016/j.ijrobp.2017.10.034. Epub 2017 Oct 31.
To report our experience with surgery, intraoperative radiation therapy (IORT), and external beam radiation therapy (EBRT) in retroperitoneal soft-tissue sarcoma.
We conducted a retrospective evaluation of 156 patients (69 primary, 87 recurrent) treated with IORT since 1991. The dominant histology was dedifferentiated liposarcoma (49%); 89% of lesions were high grade. Median tumor size was 11 cm. Surgery resulted in gross complete resection in 92%, and 65% had microscopically positive margins. Median IORT dose was 15 Gy. A total of 114 patients (73%) received additional EBRT (preoperatively n=38, postoperatively n=76, median dose 45 Gy).
Median follow-up was 38 months (49 months in survivors). The 3- and 5-year local control (LC) rates were 57% and 50%, respectively. On univariate analysis, LC was significantly associated with primary versus recurrent status, histology, grade, Union for International Cancer Control (UICC) stage, resection margin, and addition of EBRT. The 5-year LC was 71% in the primary situation and 79% after R0 resection. On multivariate analysis only disease status, grade, resection margin, and addition of EBRT remained statistically significant. The 3- and 5-year overall survival (OS) rates were 66% and 56%. On univariate analysis, OS was significantly associated with primary versus recurrent status, histology, grade, UICC stage, resection margin, and timing of EBRT. The 5-year OS was 63% in the primary situation and 68% after R0 resection. On multivariate analysis only disease status, grade, and resection margin remained independent prognostic factors. Perioperative mortality was 1%, and major complications occurred in 34% (mainly wound complications).
Treatment with surgery, IORT, and EBRT is feasible and resulted in good LC and OS, with acceptable morbidity in this unfavorable patient cohort. Incomplete resection and recurrent status resulted in clearly inferior outcomes. Reasonable efforts should be made during primary treatment to prevent the onset of a local recurrence.
报告我们在腹膜后软组织肉瘤中采用手术、术中放疗(IORT)和外束放疗(EBRT)的经验。
我们对 1991 年以来接受 IORT 治疗的 156 例患者(69 例原发性,87 例复发性)进行了回顾性评估。主要组织学类型为去分化脂肪肉瘤(49%);89%的病变为高级别。肿瘤大小中位数为 11cm。手术导致 92%的大体完全切除,65%的患者显微镜下有阳性切缘。IORT 剂量中位数为 15Gy。共有 114 例(73%)患者接受了额外的 EBRT(术前 38 例,术后 76 例,中位剂量 45Gy)。
中位随访时间为 38 个月(幸存者为 49 个月)。3 年和 5 年局部控制(LC)率分别为 57%和 50%。单因素分析显示,LC 与原发性与复发性、组织学、分级、国际抗癌联盟(UICC)分期、切缘和 EBRT 加用显著相关。原发性患者的 5 年 LC 为 71%,R0 切除后的 LC 为 79%。多因素分析仅疾病状态、分级、切缘和 EBRT 加用仍有统计学意义。3 年和 5 年总生存率(OS)分别为 66%和 56%。单因素分析显示,OS 与原发性与复发性、组织学、分级、UICC 分期、切缘和 EBRT 时机显著相关。原发性患者的 5 年 OS 为 63%,R0 切除后的 OS 为 68%。多因素分析仅疾病状态、分级和切缘是独立的预后因素。围手术期死亡率为 1%,34%(主要为伤口并发症)发生严重并发症。
手术、IORT 和 EBRT 的综合治疗是可行的,在这个预后不良的患者群体中,可获得良好的 LC 和 OS,且发病率可接受。不完全切除和复发状态导致明显较差的结果。在原发性治疗中应合理努力,以预防局部复发的发生。